Biography

Kayleigh joined Keele University as a Research Associate in Epidemiology and Biostatistics in 2020. Kayleigh previously worked as a Research Associate following her PhD in Medicine (2014) and BSc in Pharmacology (2010) at The University of Manchester.

Kayleigh currently works on a study funded by the Nuffield Foundation titled “The impact of musculoskeletal conditions on outcomes of other illnesses: a linked electronic health record study”.

Research and scholarship

Kayleigh’s expertise and research interests include analysing complex, longitudinal, real-world data and translating those findings into practical information for patients, healthcare professionals and the public.

Selected Publications

  • Mason KJ, Burden AD, Barker JNWN, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod AD. 2021. Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non‐biologic systemic therapies. Journal of the European Academy of Dermatology and Venereology, 1-3. doi> link> full text>
  • Mason KJ, Burden AD, Barker JNWN, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod AD, BADBIR Study Group. 2021. Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR. J Eur Acad Dermatol Venereol. link> doi>
  • Mahil SK, Yates M, Langan SM, Yiu ZZN, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Bruce IN, Capon F, Contreras CR, Cope AP, De La Cruz C, Di Meglio P, Gisondi P, Hyrich K, Jullien D, Lambert J, Marzo-Ortega H, McInnes I, Naldi L, Norton S, Puig L, Sengupta R, Spuls P, Torres T, Warren RB, Waweru H, Weinman J, Griffiths CEM, Barker JN, Brown MA, Galloway JB, Smith CH, PsoProtect, CORE-UK study groups. 2020. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. Br J Dermatol. link> doi>
  • Yiu ZZN, Mason KJ, Smith CH, Griffiths CEM, BADBIR Study Group. 2020. The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology. Br J Dermatol, 981-983, vol. 183(6). link> doi>
  • Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB, BADBIR Study Group. 2021. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatol, 66-73, vol. 157(1). link> doi> full text>

Full Publications Listshow

Journal Articles

  • Mason KJ, Burden AD, Barker JNWN, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod AD. 2021. Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non‐biologic systemic therapies. Journal of the European Academy of Dermatology and Venereology, 1-3. doi> link> full text>
  • Mason KJ, Burden AD, Barker JNWN, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod AD, BADBIR Study Group. 2021. Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR. J Eur Acad Dermatol Venereol. link> doi>
  • Mahil SK, Yates M, Langan SM, Yiu ZZN, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Bruce IN, Capon F, Contreras CR, Cope AP, De La Cruz C, Di Meglio P, Gisondi P, Hyrich K, Jullien D, Lambert J, Marzo-Ortega H, McInnes I, Naldi L, Norton S, Puig L, Sengupta R, Spuls P, Torres T, Warren RB, Waweru H, Weinman J, Griffiths CEM, Barker JN, Brown MA, Galloway JB, Smith CH, PsoProtect, CORE-UK study groups. 2020. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. Br J Dermatol. link> doi>
  • Yiu ZZN, Mason KJ, Smith CH, Griffiths CEM, BADBIR Study Group. 2020. The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology. Br J Dermatol, 981-983, vol. 183(6). link> doi>
  • Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB, BADBIR Study Group. 2021. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatol, 66-73, vol. 157(1). link> doi> full text>
  • Loeff FC, Tsakok T, Dijk L, Hart MH, Duckworth M, Baudry D, Russell A, Dand N, van Leeuwen A, Griffiths CEM, Reynolds NJ, Barker J, Burden AD, Warren RB, de Vries A, Bloem K, Wolbink GJ, Smith CH, Rispens T, BADBIR, BSTOP Study Groups, PSORT consortium. 2020. Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. J Invest Dermatol, 2129-2137, vol. 140(11). link> doi>
  • Mahil SK, Dand N, Mason KJ, Yiu ZZN, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Choon SE, Naldi L, Lambert J, Spuls P, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Di Meglio P, Langan SM, Capon F, Griffiths CEM, Barker JN, Smith CH, PsoProtect study group. 2021. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol, 60-71, vol. 147(1). link> doi> full text>
  • Esse S, Mason KJ, Green AC, Warren RB. 2020. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis. JAMA Dermatology. link> doi> link>
  • Mahil SK, Yiu ZZN, Mason KJ, Dand N, Coker B, Wall D, Fletcher G, Bosma A, Capon F, Iversen L, Langan SM, Di Meglio P, Musters AH, Prieto-Merino D, Tsakok T, Warren RB, Flohr C, Spuls PI, Griffiths CEM, Barker J, Irvine AD, Smith CH, Secure-AD and PsoProtect study groups. 2020. Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. British Journal of Dermatology, 404-406, vol. 183(2). link> doi> link> full text>
  • Rungapiromnan W, Mason KJ, Lunt M, McElhone K, Burden AD, Rutter MK, Warren RB, Griffiths CEM, Ashcroft DM, BADBIR Study Group. 2020. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. J Eur Acad Dermatol Venereol, 769-778, vol. 34(4). link> doi> full text>
  • Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB, BADBIR Study Group. 2020. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology, 294-302, vol. 183(2). link> doi> link> full text>
  • Al-Janabi A, Foulkes AC, Mason K, Smith CH, Griffiths CEM, Warren RB. 2020. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol, 1440-1448, vol. 34(7). link> doi>
  • Pan S, Tsakok T, Dand N, Lonsdale DO, Loeff FC, Bloem K, de Vries A, Baudry D, Duckworth M, Mahil S, Pushpa-Rajah A, Russell A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, David Burden A, Rispens T, Standing JF, Smith CH, BADBIR Study Group, the BSTOP Study Group, the PSORT Consortium. 2020. Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. Clinical and Translational Science, 400-409, vol. 13(2). link> doi> link> full text>
  • Tsakok T, Wilson N, Dand N, Loeff FC, Bloem K, Baudry D, Duckworth M, Pan S, Pushpa-Rajah A, Standing JF, de Vries A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, Burden AD, Rispens T, Stocken D, Smith C, British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) Study Group and the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) Consortium. 2019. Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. JAMA Dermatol, 1235-1243, vol. 155(11). link> doi>
  • Yiu ZZN, Mason KJ, Barker JNWN, Hampton PJ, McElhone K, Smith CH, Warren RB, Griffiths CEM, Lunt M, Burden AD, BADBIR Study Group. 2019. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. British Journal of Dermatology, 1265-1271, vol. 181(6). link> doi> link> full text>
  • Yiu ZZN, Sorbe C, Lunt M, Rustenbach SJ, Kühl L, Augustin M, Mason KJ, Ashcroft DM, Griffiths CEM, Warren RB, BADBIR Study Group. 2019. Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. Br J Dermatol, 894-901, vol. 180(4). link> doi> full text>
  • Mason KJ, Williams S, Yiu ZZN, McElhone K, Ashcroft DM, Kleyn CE, Jabbar-Lopez ZK, Owen CM, Reynolds NJ, Smith CH, Wilson N, Warren RB, Griffiths CEM. 2019. Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. British Journal of Dermatology, 256-264, vol. 181(2). link> doi> link> full text>
  • Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, Evans I, Mason KJ, Alsharqi A, Becher G, Burden AD, Goodwin RG, McKenna K, Murphy R, Perera GK, Rotarescu R, Wahie S, Wright A, Reynolds NJ, Warren RB, Griffiths CEM, Smith CH, Simpson MA, Barker JN, BADBIR Study Group, BSTOP Study Group, PSORT Consortium. 2018. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 2120-2130, vol. 143(6). link> doi> link> full text>
  • Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, Reynolds NJ, Stocken D, Emsley R, Griffiths CEM, Smith C, PSORT Consortium and on behalf of the BADBIR Study Group. 2018. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 1069-1076, vol. 180(5). link> doi> link> full text>
  • Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB, BADBIR Study Group. 2019. Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol, 329-337, vol. 180(2). link> doi> full text>
  • Garcia-Doval I, Descalzo MA, Mason KJ, Cohen AD, Ormerod AD, Gómez-García FJ, Cazzaniga S, Feldhamer I, Ali H, Herrera-Acosta E, Griffiths CEM, Stern RS, Naldi L, Psonet Network. 2018. Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland. Br J Dermatol, 863-871, vol. 179(4). link> doi>
  • Mason KJ, Barker JNWN, Smith CH. 2018. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible And Ineligible Patients in BADBIR (vol 154, pg 581, 2018). JAMA DERMATOLOGY, 852, vol. 154(7). link> doi>
  • Mason KJ, Barker JNWN, Smith CH, Hampton PJ, Lunt M, McElhone K, Warren RB, Yiu ZZN, Griffiths CEM, Burden AD, BADBIR Study Group. 2018. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 581-588, vol. 154(5). link> doi> link> full text>
  • Iskandar IYK, Warren RB, Lunt M, Mason KJ, Evans I, McElhone K, Smith CH, Reynolds NJ, Ashcroft DM, Griffiths CEM, BADBIR Study Group. 2018. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol, 775-784, vol. 138(4). link> doi> full text>
  • Mason KJ, O'Neill TW, Lunt M, Jones AKP, McBeth J. 2018. Psychosocial factors partially mediate the relationship between mechanical hyperalgesia and self-reported pain. Scand J Pain, 59-69, vol. 18(1). link> doi>
  • Peleva E, Exton LS, Kelley K, Kleyn CE, Mason KJ, Smith CH. 2018. Risk of cancer in patients with psoriasis on biological therapies: a systematic review. Br J Dermatol, 103-113, vol. 178(1). link> doi>
  • Thorneloe RJ, Griffiths CEM, Emsley R, Ashcroft DM, Cordingley L, British Association of Dermatologists Biologic Interventions Register, Psoriasis Stratification to Optimise Relevant Therapy Study Groups. 2017. Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength. Journal of Investigative Dermatology, 785-794, vol. 138(4). link> doi> link> full text>
  • Davison NJ, Warren RB, Mason KJ, McElhone K, Kirby B, Burden AD, Smith CH, Payne K, Griffiths CEM. 2017. Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. Br J Dermatol, 828-836, vol. 177(3). link> doi>

Other

  • Mahil S, Dand N, Mason K, Yiu Z, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Calzavara Pinton P, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh E, Feldman S, McMahon D, Freeman E, Gisondi P, Puig L, Warren R, Di Meglio P, Langan S, Capon F, Griffiths C, Barker J, Smith C. 2020. Factors associated with hospitalization due to COVID-19 in patients with psoriasis: insights from a global registry. BRITISH JOURNAL OF DERMATOLOGY (p. 200, vol. 183). link>
  • Rungapiromnan W, Mason KJ, Lunt M, McElhone K, Rutter MK, Warren RB, Griffiths CEM, Ashcroft DM, Grp BADBIRS. 2019. Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR). PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (p. 467, vol. 27). Journal of the European Academy of Dermatology and Venereology. link> doi> link> full text>
  • Mason KJ and Grp BADBIRS. 2019. Real-world effectiveness of methotrexate, ciclosporin, acitretin and fumaric acid esters for psoriasis: Does treatment history matter?. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (p. 503, vol. 28). link>
  • Reid C, Mason KJ, Esse S, McElhone K, Lunt M, Cordingley L, Reynolds NJ, Griffiths CEM, Warren RB. 2019. Baseline characteristics of patients registering to the British Association of Dermatologists Biologics and Immunomodulators Register stratified by duration of psoriasis at the time of registration. BRITISH JOURNAL OF DERMATOLOGY (p. 47, vol. 181). link>
  • Mason KJ, Smith C, Williams S, Lunt M, Yiu Z, McElhone K, Ashcroft DM, Kleyn CE, Jabbar-Lopez ZK, Owen C, Stocken D, Wilson N, Warren RB, Griffiths CEM, Reynolds NJ, Grp BADBIRS. 2019. Main Plenary Sessions. BRITISH JOURNAL OF DERMATOLOGY (pp. 10-11, vol. 181). link> doi>
  • Esse S, Mason KJ, Green AC, Warren RB. 2019. The risk of melanoma in patients with immune-mediated inflammatory diseases exposed to biological therapies: systematic review and meta-analysis. BRITISH JOURNAL OF DERMATOLOGY (p. 60, vol. 181). link>
  • Mason KJ and Grp BADBIRS. 2019. Real-world drug discontinuation of acitretin (ACI), ciclosporin (CsA), fumaric acid esters (FAE) and methotrexate (MTX) in patients with moderate-severe psoriasis. JOURNAL OF INVESTIGATIVE DERMATOLOGY (p. S39, vol. 139). link>
  • Yiu Z, Mason K, Barker J, Hampton P, McElhone K, Smith C, Warren R, Griffiths C, Lunt M, Burden D. 2018. A propensity-score weighting approach to compare registry and trial populations of patients with psoriasis on biologic therapies. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (p. 49, vol. 27). link>
  • Mason KJ. 2018. A real-world comparison of effectiveness and safety outcomes between clinical trial eligible and ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR). PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (pp. 16-17, vol. 27). link>
  • Williams S, Mason KJ, Yiu Z, McElhone K, Warren RB, Griffiths CEM. 2018. Real-world persistence and effectiveness of conventional systemic therapies in the treatment of psoriasis: A systematic review. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (p. 408, vol. 27). link>
  • Mason KJ. 2018. The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared with conventional systemic therapy: Results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (p. 17, vol. 27). link>
  • Rungapiromnan W, Mason KJ, Lunt M, McElhone K, Rutter MK, Warren RB, Griffiths CEM, Ashcroft DM, Grp BS. 2018. Association between biologics and major cardiovascular events in adult patients with plaque psoriasis: A cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR). JOURNAL OF INVESTIGATIVE DERMATOLOGY (p. S87, vol. 138). link>
  • Mason KJ. 2018. The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared to conventional systemic therapy: Results from The British Association of Dermatologists Biologic Interventions Register (BADBIR). JOURNAL OF INVESTIGATIVE DERMATOLOGY (p. S41, vol. 138). link>
  • Mason K. 2018. THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES. ACTA DERMATO-VENEREOLOGICA (p. 33, vol. 98). link>
  • Mason KJ, Barker JNWN, Smith CH, Hampton PJ, Lunt M, McElhone K, Warren RB, Yiu ZZN, Griffiths CEM, Burden AD, Grp BADBIRS. 2017. A real-world comparison of effectiveness and safety outcomes between clinical trial-eligible and -ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR). BRITISH JOURNAL OF DERMATOLOGY (p. E273, vol. 177). link>
  • Mason KJ, Lunt M, Hunter HJ, Jabbar-Lopez ZK, Kirby B, Kleyn CE, Kreppel S, McElhone K, Reynolds NJ, Warren RB, Griffiths CEM, Grp BADBIRS. 2017. Real-world use of fumaric acid esters in psoriasis: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). BRITISH JOURNAL OF DERMATOLOGY (pp. E272-E273, vol. 177). link>
  • Mason KJ, Ali H, Reynolds NJ, Burden AD, Smith CH, Evans I, McElhone K, Steer O, Tahir S, Griffiths CEM, Grp BADBIRS. 2017. Completeness of Reporting of Overnight Hospitalisations to a Psoriasis Pharmacovigilance Register and the National Health Service Wales Informatics Service. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (pp. 564-565, vol. 26). link>
  • Iskandar IYK, Warren R, Lunt M, Mason KJ, Evans I, McElhone K, Smith C, Reynolds N, Griffiths CEM, Ashcroft DM. 2017. Persistence with second-line biological therapies in patients with psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). BRITISH JOURNAL OF DERMATOLOGY (pp. 11-12, vol. 177). link>
  • Mason KJ, Evans I, McElhone K, Lunt M, Hussain S, Kirby B, Burden A, Reynolds NJ, Griffiths CE. 2016. PATTERNS OF INDEX BIOLOGIC DRUG REGISTRATIONS TO A PHARMACOVIGILANCE REGISTER OF PSORIASIS PATIENTS. VALUE IN HEALTH (p. A573, vol. 19). link> doi>
  • Mason KJ, Lunt M, Reynolds NJ, Ashcroft DM, Burden AD, Ormerod AD, Barker JNWN, Smith CH, Green A, Ali H, Evans I, Irshad S, McElhone K, Wilde V, Griffiths CEM. 2016. Completeness of Reporting of Basal Cell Carcinoma and Squamous Cell Carcinoma to a Pharmacovigilance Register and the Health and Social Care Information Centre. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (pp. 438-439, vol. 25). link>
  • Mason KJ, Lunt M, Felson DT, Maricar N, Forsythe LM, Jones AK, McBeth J, O'Neill TW. 2014. MECHANICAL PAIN THRESHOLD PREDICTS RESPONSE TO INTRA-ARTICULAR STEROID THERAPY IN SYMPTOMATIC KNEE OSTEOARTHRITIS. OSTEOARTHRITIS AND CARTILAGE (pp. S408-S409, vol. 22). link> doi>

Collaborations and grants awards

  • Sep 2020 - Translation@Manchester Informatics Training Scheme, Wellcome Trust
  • May 2019 - Albert M. Kligman Travel Fellowship, Society for Investigative Dermatology
  • June 2018 - Best Oral Presentation, British Dermatology Nursing Group Annual Conference
  • Jan 2018 - PhD Studentship, The Psoriasis Association (£84,000; 40% award as supervisor)
  • Sep 2010 – PhD Studentship, Arthritis Research UK (Margaret Coupe Endowment)